5.90MMarket Cap-0.37P/E (TTM)
2.3900High2.2200Low103.58KVolume2.3000Open2.2700Pre Close237.83KTurnover4.13%Turnover RatioLossP/E (Static)2.51MShares14.918452wk High0.99P/B5.89MFloat Cap1.830152wk Low--Dividend TTM2.51MShs Float719999.6400Historical High--Div YieldTTM7.49%Amplitude1.8300Historical Low2.2960Avg Price1Lot Size
Soligenix Stock Forum
🚀🚀🚀
Can this stock run like $Phio Pharmaceuticals (PHIO.US)$ and $Salarius Pharmaceuticals (SLRX.US)$ ?
EXCLUSIVE: Soligenix Tells Benzinga 'Study Supported by $2.6 Million FDA Orphan Products Development Grant'
Soligenix
Tells Benzinga HyBryte Expanded
Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma
Tells Benzinga 'Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving "Treatment Success'
Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
'Study Supported by $2.6 Million FDA Orphan Products Development...
EXCLUSIVE: Soligenix Tells Benzinga Co. Initiates Confirmatory Phase III Trial Of HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix Tells
Benzinga Co. Initiates Confirmatory
Phase III Trial Of HyBryte For The Treatment Ot Cutaneous T-Cell
Lymphoma
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Monday, 16th December at 7:30 am
FLASH2 Study opens patient enrollment
PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on devel...
No comment yet